In this video interview with SOHO Insider, Pan-Yu Chen, PhD, an associate director of Translational Medicine at the clinical-stage biopharmaceutical company Opna Bio, discusses research on novel targeted protein degraders in multiple myeloma that was presented at the 67th American Society of Hematology Annual Meeting and Exposition in Orlando, Florida.
Dr. Chen spoke about the new protein degraders designed to target EP300/CBP and IKZF1/3 in multiple myeloma, including the first-generation agent, OPN-5667, and a more potent second-generation degrader, OPN-5877. She also discussed what these new therapies could potentially mean for patients.
Reference
Chen P-Y, Chowdhury S, Zeng SQ. Novel multifunctional degraders of EP300/CBP and IKZF1/3 with potent anti-myeloma activity. Abstract #573. Presented at 2025 American Society of Hematology Annual Meeting & Exposition. December 6–9; Orlando, Florida.
